Trianni, Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a license agreement under which Takeda will have access to the Trianni Mouse, a monoclonal antibody discovery platform that has been optimized for the isolation of fully human therapeutics.   “We are very pleased to see Takeda adopt the Trianni Mouse,” said Dr. Matthias Wabl, Ph.D., chairman and chief executive officer of Trianni. “With its many distinctive features, most notably a full repertoire expressed from...